Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP104146.RAfg82pse69KwaCF12le5sjBYdg48YSt7T24L8__9Si60130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP104146.RAfg82pse69KwaCF12le5sjBYdg48YSt7T24L8__9Si60130_provenance.
• NP114741.RAdxc-DYI23yFO3BLFmt2dxMRX57I4R-l313Xp194uYG0130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP114741.RAdxc-DYI23yFO3BLFmt2dxMRX57I4R-l313Xp194uYG0130_provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP126182.RASsEDIl3nZySizyIRoQ7oKI8a5jR0SHhcUbMDdX8U7MI130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126182.RASsEDIl3nZySizyIRoQ7oKI8a5jR0SHhcUbMDdX8U7MI130_provenance.
• NP126190.RARb1Fk0FTYw2i3j34BKH8fjH60xIGSjOh2JIHVAjfdGI130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126190.RARb1Fk0FTYw2i3j34BKH8fjH60xIGSjOh2JIHVAjfdGI130_provenance.
• NP115910.RAjaHO7Iz3fbuLN3VfT4XbfqPIyT8wjoYW2Mw2t09WP9E130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP115910.RAjaHO7Iz3fbuLN3VfT4XbfqPIyT8wjoYW2Mw2t09WP9E130_provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP126187.RAnFWIpHC8Ab1QQYS4IdK8zqKoMA9xNxuy2YyVvmuVsY4130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126187.RAnFWIpHC8Ab1QQYS4IdK8zqKoMA9xNxuy2YyVvmuVsY4130_provenance.
• NP126194.RAm-uKf80ZwMsWsJHipmgVw_juwADVkEhIwB4m6h4IDmM130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126194.RAm-uKf80ZwMsWsJHipmgVw_juwADVkEhIwB4m6h4IDmM130_provenance.
• NP110509.RAwSapP1vD11FsNEP-mJYsFJj26Il1NLY2TpR-rf89ZrY130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP110509.RAwSapP1vD11FsNEP-mJYsFJj26Il1NLY2TpR-rf89ZrY130_provenance.
• NP114445.RA-77tNFZn8xCHLBfLeAsbIsLUwV4K46xZ50DI3EP7UMA130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP114445.RA-77tNFZn8xCHLBfLeAsbIsLUwV4K46xZ50DI3EP7UMA130_provenance.
• NP115970.RA8PrHTiDAOmA7KG3PXuLtUXYozm5fQ61g9CYGBONwrTM130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP115970.RA8PrHTiDAOmA7KG3PXuLtUXYozm5fQ61g9CYGBONwrTM130_provenance.
• NP102119.RAKe9uB3iGbIjJbU1KFw37rW01iRIczmnBGBkXjzjdZTk130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP102119.RAKe9uB3iGbIjJbU1KFw37rW01iRIczmnBGBkXjzjdZTk130_provenance.
• NP126184.RAF4m8MvNSeWHYEZckxIpCPNkuODy5tR9Kv8KFgM-tS4Q130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126184.RAF4m8MvNSeWHYEZckxIpCPNkuODy5tR9Kv8KFgM-tS4Q130_provenance.
• NP126188.RALThVQyjVGAjqu4XXuDiPA-HwDpZ9kJ97NEnpNkcK9LM130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126188.RALThVQyjVGAjqu4XXuDiPA-HwDpZ9kJ97NEnpNkcK9LM130_provenance.
• NP126191.RAPZ_FTA_tVsa2cRDkEejWSlcfX-DxKDU1lARW8XSv_yw130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126191.RAPZ_FTA_tVsa2cRDkEejWSlcfX-DxKDU1lARW8XSv_yw130_provenance.
• NP126193.RAH_3_ZuLYvAx4am1zRIpvFgiovEKaQFdtagFX1CTZm9Y130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126193.RAH_3_ZuLYvAx4am1zRIpvFgiovEKaQFdtagFX1CTZm9Y130_provenance.
• NP126195.RAIKLxzhZYW4JVDfboYel9BWfFzYCvo8eRFjMeGk2S8lA130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126195.RAIKLxzhZYW4JVDfboYel9BWfFzYCvo8eRFjMeGk2S8lA130_provenance.
• NP126183.RA0TDKbs5po-r6YTh2_KwePo7FfKSBmeE8GtV9sFXb2zU130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126183.RA0TDKbs5po-r6YTh2_KwePo7FfKSBmeE8GtV9sFXb2zU130_provenance.
• NP126185.RA_g7tvMVQcQkTd7vqLpi5jTNlYijOiSwb-ESZhLFMztg130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126185.RA_g7tvMVQcQkTd7vqLpi5jTNlYijOiSwb-ESZhLFMztg130_provenance.
• NP126186.RA0SPBYzIvitNVIbM79xSSyfD9zNS1Ry8iHLz8ZkVNbIY130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126186.RA0SPBYzIvitNVIbM79xSSyfD9zNS1Ry8iHLz8ZkVNbIY130_provenance.
• NP126189.RA6zSrrCoPsv_CIswf-wQ0-BcrlSLrfTsxX7pyuY7rAgc130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126189.RA6zSrrCoPsv_CIswf-wQ0-BcrlSLrfTsxX7pyuY7rAgc130_provenance.
• NP126192.RA7VAocAnFjwDmPgf9lDSmE_8pFEjaPVo_kC4kyE_oIEQ130_assertion description "[Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP126192.RA7VAocAnFjwDmPgf9lDSmE_8pFEjaPVo_kC4kyE_oIEQ130_provenance.